Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Obamacare enrollment declines as US subsidies expire - 2The most effective method to Pick the Right Material Organization: Your Definitive Aide
- 3Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
- 4People can't get enough of this couple's Hallmark movie reviews. They don't know the painful backstory.
- 5Grasping the Basics of Business Land Regulation
- Instructions to Choose the Best Material Organization for a Fruitful Rooftop Substitution
- 10 Natural products to Remember for Your Eating routine for a Better You
- Greece eyes migrant repatriation centres outside the EU
- Finding the Universe of Workmanship: Individual Encounters in Imagination
- We tasted one of the 10,000 Hershey's Dubai chocolate bars being resold on eBay. Is it worth the hype?
- 5 Great High-Mileage Electric Vehicles Of 2024
- Dental, Vision, and Hearing Inclusion in Senior Protection.
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- The Electric Bicycle Americans Can Confide in 2024
